Vaughan Nelson Investment Management L.P. Sells 216,025 Shares of Zoetis Inc. $ZTS

Key Points

• Vaughan Nelson Investment Management L.P. sold 216,025 shares of Zoetis Inc., reducing its stake by 17.8% to approximately 999,038 shares, representing around 1.5% of its portfolio.
• Several institutional investors, including Vanguard Group Inc. and Polen Capital Management LLC, have increased their holdings in Zoetis, reflecting strong overall interest in the stock.
• Zoetis recently reported a quarterly earnings per share (EPS) of $1.76, beating analysts' expectations by $0.14, with a revenue of $2.46 billion, exceeding projections of $2.41 billion.

Vaughan Nelson Investment Management L.P. reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 17.8% during the second quarter, according to its most recent filing with the SEC. The fund owned 999,038 shares of the company's stock after selling 216,025 shares during the quarter. Zoetis accounts for approximately 1.5% of Vaughan Nelson Investment Management L.P.'s portfolio, making the stock its 17th largest holding. Vaughan Nelson Investment Management L.P. owned 0.22% of Zoetis worth $155,800,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC increased its position in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the last quarter. Northern Trust Corp increased its position in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after purchasing an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock valued at $847,293,000 after acquiring an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. grew its position in Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock valued at $725,866,000 after acquiring an additional 312,746 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZTS. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zoetis in a research note on Saturday, September 27th. Argus reissued a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and reduced their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Stock Down 0.0%

ZTS stock opened at $146.45 on Friday. The business's 50-day moving average price is $149.79 and its 200-day moving average price is $155.14. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The stock has a market cap of $64.91 billion, a P/E ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.